Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

Completed · Phase 1 · Has a placebo group

Conditions studied: Mild Cognitive Impairment, Alzheimer Disease

In brief

The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose.

Key facts

Study ID
NCT02221622
Run by
University of Southern California
People needed
24
Starts
2014-08-01
Expected to finish
2018-02-01
Last updated by the study team
2019-07-05

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.